Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 389,477 | 211,885 | 923,031 | 1,168,620 | 943,771 |
| Marketable Securities | 1,304,215 | 1,603,433 | 1,456,098 | 521,713 | N/A |
| Receivables | 200,000 | N/A | 305 | 144 | 99 |
| TOTAL | $1,908,078 | $1,853,026 | $2,417,513 | $1,716,620 | $987,547 |
| Non-Current Assets | |||||
| PPE Net | 151,945 | 163,634 | 137,575 | 42,160 | 31,330 |
| Investments And Advances | 1,973 | 53,130 | 0 | 0 | 0 |
| Intangibles | 16 | 71 | 125 | 180 | 235 |
| Other Non-Current Assets | 167,559 | 173,196 | 196,664 | 69,006 | 47,640 |
| TOTAL | $321,493 | $390,031 | $334,364 | $111,346 | $79,205 |
| Total Assets | $2,229,571 | $2,243,057 | $2,751,877 | $1,827,966 | $1,066,752 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 38,147 | 27,428 | 14,816 | 9,094 | 5,944 |
| Accrued Expenses | 45,773 | 77,817 | 91,727 | 64,255 | 30,763 |
| Other current liabilities | 5,141 | 20 | 171 | 7,207 | 10,950 |
| TOTAL | $108,791 | $121,107 | $119,883 | $94,259 | $57,106 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 4,105 | N/A | 1,011 | 2,341 | 960 |
| Other Non-Current Liabilities | 223,965 | 234,148 | 220,211 | 69,473 | 58,445 |
| TOTAL | $237,977 | $246,471 | $232,534 | $69,473 | $70,221 |
| Total Liabilities | $346,768 | $367,578 | $352,417 | $163,732 | $127,327 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 80,276 | 78,647 | 77,068 | 75,429 | 60,846 |
| Common Shares | 2,497 | 2,441 | 2,391 | 2,277 | 1,847 |
| Retained earnings | -999,700 | -846,090 | -195,915 | -573,576 | -224,711 |
| Other shareholders' equity | 1,851 | -15,710 | -5,130 | -146 | -56 |
| TOTAL | $1,882,803 | $1,875,479 | $2,399,460 | $1,664,234 | $939,425 |
| Total Liabilities And Equity | $2,229,571 | $2,243,057 | $2,751,877 | $1,827,966 | $1,066,752 |